Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.61 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934758 | 0.90 | PTGDR2 (0.63) | PTGDR2CYP2C8CYP2C9CYP2C19BCHE | |
| SCHEMBL934629 | 0.90 | PTGDR2 (0.62) | PTGDR2CYP2C8CYP2C9CYP2C19TSPO | |
| SCHEMBL934298 | 0.88 | PTGDR2 (0.59) | PTGDR2CYP2C8CYP2C9CYP2C19TSPO | |
| SCHEMBL933859 | 0.87 | PTGDR2 (0.58) | PTGDR2RAB9ATSPOPTGESALOX5 | |
| SCHEMBL934745 | 0.86 | PTGDR2 (0.59) | PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL933905 | 0.85 | PTGDR2 (0.46) | PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL934765 | 0.82 | PTGDR2 (0.44) | PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL934632 | 0.81 | PTGDR2 (0.47) | PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL934274 | 0.80 | PTGDR2 (0.57) | PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL935230 | 0.80 | PTGDR2 (0.65) | PTGDR2CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454243-A2 | TETRAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006935-A2 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | TSLP, IL5, CMA1 | PTGDR2 548/4885CYP2C8 108/4885CYP2C9 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.